De Vries T J, De Wit P E, Clemmensen I, Verspaget H W, Weidle U H, Bröcker E B, Ruiter D J, Van Muijen G N
Department of Pathology, University Hospital, Nijmegen, The Netherlands.
J Pathol. 1996 Jul;179(3):260-5. doi: 10.1002/(SICI)1096-9896(199607)179:3<260::AID-PATH586>3.0.CO;2-T.
The induction of expression of the components of the proteolytic plasminogen activation system in cutaneous melanocytic tumour progression has previously been reported. Plasminogen activators, their inhibitors, and the receptor for urokinase were present only in advanced primary melanomas and melanoma metastases. The present study reports on the presence of tetranectin and plasmin/ plasminogen, two proteins connected with plasminogen activation, in cutaneous melanocytic lesions. The distribution of tetranectin and plasminogen was studied by immunohistochemistry in 105 freshly frozen melanocytic lesions of common naevocellular naevi (n = 24), atypical naevi (n = 14), early (n = 12) and advanced (n = 20) primary melanomas, and melanoma metastases (n = 35). Both tetranectin and plasminogen were detected in a variety of tissue components. In all stages of melanocytic tumour progression, tetranectin was found in endothelium, perivascular dendritic cells, and leukocytes. Plasminogen was present in endothelium and in the basal layer of the normal skin. Tetranectin and plasminogen staining of fibroblastic cells at the invasive front and of extracellular matrix was, however, restricted to malignant lesions. Co-localization of tetranectin and plasminogen was found in 50 per cent of the early primary melanomas and in more than 75 per cent of the advanced melanomas and melanoma metastases. These results suggest a coordinated role for tetranectin and plasminogen at the invasive front of melanomas. Tetranectin-bound plasminogen may facilitate the migration of tumour cells.
先前已有报道称，在皮肤黑素细胞肿瘤进展过程中，蛋白水解性纤溶酶原激活系统的成分会被诱导表达。纤溶酶原激活剂、其抑制剂以及尿激酶受体仅存在于晚期原发性黑色素瘤和黑色素瘤转移灶中。本研究报道了与纤溶酶原激活相关的两种蛋白——四聚体蛋白和纤溶酶/纤溶酶原在皮肤黑素细胞病变中的存在情况。通过免疫组织化学方法，对105例新鲜冷冻的黑素细胞病变进行了研究，这些病变包括普通痣细胞痣（n = 24）、非典型痣（n = 14）、早期（n = 12）和晚期（n = 20）原发性黑色素瘤以及黑色素瘤转移灶（n = 35）。在多种组织成分中均检测到了四聚体蛋白和纤溶酶原。在黑素细胞肿瘤进展的各个阶段，在内皮细胞、血管周围树突状细胞和白细胞中均发现了四聚体蛋白。纤溶酶原存在于内皮细胞和正常皮肤的基底层。然而，侵袭前沿的成纤维细胞和细胞外基质的四聚体蛋白和纤溶酶原染色仅限于恶性病变。在50%的早期原发性黑色素瘤以及超过75%的晚期黑色素瘤和黑色素瘤转移灶中发现了四聚体蛋白和纤溶酶原的共定位。这些结果表明，四聚体蛋白和纤溶酶原在黑色素瘤的侵袭前沿发挥协同作用。与四聚体蛋白结合的纤溶酶原可能促进肿瘤细胞的迁移。
